195 related articles for article (PubMed ID: 27099475)
1. In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma.
Xue C; Tian Y; Zhang J; Zhao Y; Zhan J; Fang W; Zhang L
Drug Des Devel Ther; 2016; 10():1299-306. PubMed ID: 27099475
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine synergizes with cisplatin to inhibit nasopharyngeal carcinoma cell proliferation and tumor growth.
He SW; Zhang Y; Chen L; Luo WJ; Li XM; Chen Y; Huang SY; He QM; Yang XJ; Li YQ; Liu N; Zhao Y; Ma J
FASEB J; 2021 Oct; 35(10):e21885. PubMed ID: 34478585
[TBL] [Abstract][Full Text] [Related]
3. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo.
Zhao YY; Tian Y; Zhang J; Xu F; Yang YP; Huang Y; Zhao HY; Zhang JW; Xue C; Lam MH; Yan L; Hu ZH; Dinglin XX; Zhang L
Drug Des Devel Ther; 2014; 8():1827-37. PubMed ID: 25336925
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivo.
Xue C; Tian Y; Zhang J; Zhao Y; Zhan J; Fang W; Zhang L
Drug Des Devel Ther; 2016; 10():1173-80. PubMed ID: 27042009
[TBL] [Abstract][Full Text] [Related]
5. ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma.
Wang Y; Wang Y; Fan X; Song J; Wu H; Han J; Lu L; Weng X; Nie G
Biochem Biophys Res Commun; 2018 Sep; 503(3):1214-1220. PubMed ID: 30017199
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway.
Luo F; Lu FT; Qiu MZ; Zhou T; Ma WJ; Luo M; Zeng KM; Luo QY; Pan WT; Zhang L; Xia ZF; Zhang ZH; Cao JX; Zhao HY; Zhang L; Yang DJ
Cell Death Dis; 2021 Aug; 12(8):772. PubMed ID: 34354046
[TBL] [Abstract][Full Text] [Related]
7. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol inhibits human nasopharyngeal carcinoma cell growth via blocking pAkt/p70S6K signaling pathways.
Zhang M; Zhou X; Zhou K
Int J Mol Med; 2013 Mar; 31(3):621-7. PubMed ID: 23314035
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
[TBL] [Abstract][Full Text] [Related]
10. Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma.
Ma L; Zhang G; Miao XB; Deng XB; Wu Y; Liu Y; Jin ZR; Li XQ; Liu QZ; Sun DX; Testa JR; Yao KT; Xiao GH
FEBS J; 2013 May; 280(9):2027-41. PubMed ID: 23461856
[TBL] [Abstract][Full Text] [Related]
11. Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition.
Ioannou N; Seddon AM; Dalgleish A; Mackintosh D; Solca F; Modjtahedi H
Int J Oncol; 2016 Mar; 48(3):908-18. PubMed ID: 26781210
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
Nakajima Y; Takagi H; Kakizaki S; Horiguchi N; Sato K; Sunaga N; Mori M
Anticancer Res; 2012 Dec; 32(12):5251-62. PubMed ID: 23225424
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.
Hui EP; Lui VW; Wong CS; Ma BB; Lau CP; Cheung CS; Ho K; Cheng SH; Ng MH; Chan AT
Invest New Drugs; 2011 Dec; 29(6):1123-31. PubMed ID: 20467883
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.
Higgins B; Kolinsky K; Smith M; Beck G; Rashed M; Adames V; Linn M; Wheeldon E; Gand L; Birnboeck H; Hoffmann G
Anticancer Drugs; 2004 Jun; 15(5):503-12. PubMed ID: 15166626
[TBL] [Abstract][Full Text] [Related]
15. A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation.
Chan KC; Ting CM; Chan PS; Lo MC; Lo KW; Curry JE; Smyth T; Lee AW; Ng WT; Tsao GS; Wong RN; Lung ML; Mak NK
Mol Cancer; 2013 Oct; 12(1):128. PubMed ID: 24156782
[TBL] [Abstract][Full Text] [Related]
16. Precise engineering of hybrid molecules-loaded macromolecular nanoparticles shows
Liu D; Zhang W; Liu X; Qiu R
Drug Deliv; 2021 Dec; 28(1):776-786. PubMed ID: 33866910
[TBL] [Abstract][Full Text] [Related]
17. [Effect of epidermal growth factor receptor-selective tyrosine kinase inhibitor gefitinib on nasopharyngeal carcinoma xenografts].
Wang SS; Guan ZZ; Xiang YQ; Jiang WQ; Lin TY; Zhang L
Ai Zheng; 2004 Nov; 23(11 Suppl):1365-9. PubMed ID: 15566638
[TBL] [Abstract][Full Text] [Related]
18. Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase.
Xiao X; Wu J; Zhu X; Zhao P; Zhou J; Liu QQ; Zheng L; Zeng M; Liu R; Huang W
Int J Cancer; 2007 Nov; 121(9):2095-2104. PubMed ID: 17631646
[TBL] [Abstract][Full Text] [Related]
19. Apigenin enhances the antitumor effects of cetuximab in nasopharyngeal carcinoma by inhibiting EGFR signaling.
Hu WJ; Liu J; Zhong LK; Wang J
Biomed Pharmacother; 2018 Jun; 102():681-688. PubMed ID: 29604587
[TBL] [Abstract][Full Text] [Related]
20. Jervine exhibits anticancer effects on nasopharyngeal carcinoma through promoting autophagic apoptosis via the blockage of Hedgehog signaling.
Chen J; Wen B; Wang Y; Wu S; Zhang X; Gu Y; Wang Z; Wang J; Zhang W; Yong J
Biomed Pharmacother; 2020 Dec; 132():110898. PubMed ID: 33113432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
